Launch of Horizon Therapeutics Public (NASDAQ:HZNP) coverage within the UBS Group
UBS Group equity analysts provided coverage of the shares of Horizon Therapeutics Public (NASDAQ:HZNP – Get Rating) in a report released on Monday, reports The Fly. The brokerage has placed a “buy” rating on the shares of the biopharmaceutical company.
Several other equity research analysts also commented on the stock. Wells Fargo & Company restated a “buy” rating and set a target price of $133.00 on shares of Horizon Therapeutics Public in a Friday, April 8 research report. Oppenheimer began covering Horizon Therapeutics Public stocks in a research report on Monday, March 14. They set an “outperform” rating and a target price of $140.00 on the stock. Morgan Stanley raised its price target on shares of Horizon Therapeutics Public from $135.00 to $140.00 and gave the stock an “overweight” rating in a Wednesday, March 2 research report. StockNews.com began covering Horizon Therapeutics Public stocks in a research report on Thursday, March 31. They have set a “holding” rating on the stock. Finally, SVB Leerink began covering Horizon Therapeutics Public stocks in a research report on Monday, May 23. They issued a “market performance” rating and a price target of $95.00 on the stock. Two equity research analysts rated the stock with a hold rating and eight gave the company a buy rating. According to MarketBeat.com, Horizon Therapeutics Public currently has a consensus rating of “Buy” and a consensus price target of $132.67.
Artificial intelligence is the #1 tool used by traders. Our AI predicts major trend reversals… 1-3 days in advance.
Take your place in our FREE, LIVE online course. Plus, ask our presenter anything via our interactive chat.
We forecast your favorite stocks, cryptos and more – live.
Shares of Horizon Therapeutics Public were down $3.82 during Monday’s trading, hitting $81.60. The company’s stock had a trading volume of 1,351,469 shares, compared to its average volume of 1,846,253. The company has a 50-day moving average price of $98.10 and a two-cent moving average price. $99.06 days. The company has a market capitalization of $18.76 billion, a PE ratio of 22.36, a P/E/G ratio of 1.20 and a beta of 1.13. Horizon Therapeutics Public has a fifty-two week low of $81.20 and a fifty-two week high of $120.54. The company has a current ratio of 3.57, a quick ratio of 3.30 and a debt ratio of 0.53.
Horizon Therapeutics Public (NASDAQ:HZNP – Get Rating) last announced its results on Wednesday, May 4. The biopharmaceutical company reported EPS of $1.34 for the quarter, beating consensus analyst estimates of $1.15 by $0.19. The company posted revenue of $885.25 million for the quarter, compared to $866.39 million expected by analysts. Horizon Therapeutics Public had a net margin of 22.87% and a return on equity of 32.08%. The company’s quarterly revenue increased 158.5% year over year. During the same period of the previous year, the company posted EPS of $0.03. On average, analysts predict Horizon Therapeutics Public will post 5.6 earnings per share for the current fiscal year.
Separately, CFO Paul W. Hoelscher sold 50,000 shares of the company in a trade dated Wednesday, April 20. The shares were sold at an average price of $114.71, for a total transaction of $5,735,500.00. Following the completion of the transaction, the CFO now owns 1,049 shares of the company, valued at approximately $120,330.79. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Additionally, Executive Vice President Andy Pasternak sold 762 shares of the company in a transaction dated Friday, June 10. The shares were sold at an average price of $85.36, for a total transaction of $65,044.32. Following the transaction, the executive vice president now directly owns 38,897 shares of the company, valued at approximately $3,320,247.92. The disclosure of this sale can be found here. In the past 90 days, insiders have sold 580,073 shares of the company worth $61,939,180. 2.50% of the shares are held by insiders.
Hedge funds and other institutional investors have recently been buying and selling shares of the company. Capital International Investors acquired a new stake in Horizon Therapeutics Public during Q1 for a value of approximately $744,453,000. Norges Bank acquired a new stake in Horizon Therapeutics Public during Q4 for a value of approximately $250,526,000. Marshall Wace LLP increased its position in Horizon Therapeutics Public by 3,782.6% during the 4th quarter. Marshall Wace LLP now owns 1,656,679 shares of the biopharmaceutical company worth $178,522,000 after purchasing an additional 1,614,010 shares last quarter. Allspring Global Investments Holdings LLC acquired a new stake in Horizon Therapeutics Public during Q4 for a value of approximately $149,271,000. Finally, 1832 Asset Management LP increased its position in Horizon Therapeutics Public by 1,492.5% during the 4th quarter. 1832 Asset Management LP now owns 1,406,500 shares of the biopharmaceutical company worth $152,084,000 after buying an additional 1,318,180 shares last quarter. 88.39% of the shares are held by institutional investors.
Horizon Therapeutics Public Company Profile (Get a rating)
Horizon Therapeutics Public Limited Company, a biotechnology company, is focused on the discovery, development and commercialization of drugs that address the critical needs of people affected by rare, autoimmune and serious inflammatory diseases. The Company operates in two segments, Orphan and Inflammation.
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in Horizon Therapeutics Public right now?
Before you consider Horizon Therapeutics Public, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Horizon Therapeutics Public was not on the list.
Although Horizon Therapeutics Public currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here